EyePoint Pharmaceuticals (NASDAQ:EYPT) Announces Earnings Results, Misses Estimates By $0.10 EPS

EyePoint Pharmaceuticals (NASDAQ:EYPT) issued its quarterly earnings results on Wednesday. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10), Zacks reports. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

EyePoint Pharmaceuticals Trading Down 0.8 %

NASDAQ EYPT traded down $0.05 on Wednesday, hitting $6.03. 82,563 shares of the stock traded hands, compared to its average volume of 833,604. The stock has a 50-day moving average of $7.31 and a 200 day moving average of $8.50. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $26.76. The company has a market capitalization of $411.49 million, a P/E ratio of -3.01 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on EYPT shares. Robert W. Baird reduced their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Citigroup started coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.